{"id":3966,"date":"2023-03-03T17:32:28","date_gmt":"2023-03-03T16:32:28","guid":{"rendered":"https:\/\/www.access2meds.eu\/consorcio\/"},"modified":"2025-06-24T10:12:35","modified_gmt":"2025-06-24T08:12:35","slug":"consorcio","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/es\/consorcio\/","title":{"rendered":"Consorcio"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ admin_label=\u00bbHeader\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bb2e264158-b54d-4d7f-8146-8c8b7ca64cef\u00bb background_image=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1200929353_SolStock-e1679656039802.jpg\u00bb background_position=\u00bbtop_center\u00bb background_last_edited=\u00bbon|phone\u00bb background_image_phone=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Mobile-Header-2.png\u00bb background_enable_image_phone=\u00bbon\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb7px|30px||30px|false|true\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb header_font=\u00bb|700||on|||||\u00bb header_text_color=\u00bb#E85D6B\u00bb header_font_size=\u00bb60px\u00bb custom_margin=\u00bb11px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Consorcio<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbfirst text colored pill\u00bb _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_enable_color=\u00bboff\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb vertical_offset=\u00bb-164px\u00bb custom_margin=\u00bb||-153px||false|false\u00bb custom_padding=\u00bb|0px||0px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.33em\u00bb header_2_font=\u00bbPoppins regular||||||||\u00bb header_2_text_color=\u00bb#FFFFFF\u00bb header_2_font_size=\u00bb24px\u00bb background_color=\u00bb#048EA3″ max_width=\u00bb635px\u00bb module_alignment=\u00bbleft\u00bb custom_padding=\u00bb60px|92px|60px|30px|true|false\u00bb custom_css_main_element=\u00bboverflow:visible;\u00bb custom_css_after=\u00bbcontent:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:635px;\u00bb border_radii=\u00bboff||999px|999px|\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Esta secci\u00f3n ofrece una visi\u00f3n general del consorcio del proyecto ASCERTAIN, incluyendo informaci\u00f3n sobre los socios del proyecto y sus respectivas funciones y responsabilidades.<\/p>\n

Somos un consorcio de socios de siete pa\u00edses (Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia) que colaboramos juntos.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb8px||36px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|30px|40px|30px|false|true\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/logo-erasmus-universiteit.png\u00bb title_text=\u00bblogo-erasmus-universiteit\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Erasmus Universiteit Rotterdam<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Erasmus Universiteit Rotterdam (EUR) se encuentra en R\u00f3terdam (Pa\u00edses Bajos), y cuenta con 3.700 miembros de personal acad\u00e9mico y 23.867 estudiantes. Erasmus School of Health Policy & Management (ESHPM) es una escuela multidisciplinar de investigaci\u00f3n y ense\u00f1anza de la universidad. Uno de sus departamentos, Institute for Medical Technology Assessment (iMTA), ha desempe\u00f1ado un papel clave en la investigaci\u00f3n sobre ETS en Pa\u00edses Bajos, Europa y el resto del mundo. El instituto ha llevado a cabo m\u00e1s de 600 proyectos de investigaci\u00f3n sanitaria patrocinados por importantes organismos de financiaci\u00f3n, como gobiernos o instituciones relacionadas con el gobierno, la Comisi\u00f3n Europea, la OMS, organizaciones sanitarias, fundaciones ben\u00e9ficas y la industria farmac\u00e9utica. <\/p>\n

Funci\u00f3n en el proyecto: <\/strong>EUR es el coordinador de este proyecto y aporta su experiencia en fijaci\u00f3n de precios, terapia g\u00e9nica y celular y reembolso.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#fbedec\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb custom_css_main_element_tablet=\u00bbwidth:20.65% !important;\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava.svg\u00bb title_text=\u00bbUniversidad_Comenius_Bratislava\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_padding_phone=\u00bb|0px|20px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb custom_css_main_element_tablet=\u00bbwidth:79.35% !important;\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb0px||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Comenius University in Bratislava (UNIBA)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Comenius University in Bratislava es una instituci\u00f3n de investigaci\u00f3n que dirige cientos de proyectos nacionales e internacionales. Un representante de la Facultad de Farmacia fue miembro del Comit\u00e9 de Reembolso de Medicamentos del Ministerio de Sanidad eslovaco en nombre del Fondo del Seguro M\u00e9dico Sindical. <\/p>\n

Funci\u00f3n en el proyecto:<\/strong> UNIBA aporta su experiencia en productos sanitarios y reembolso.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#FFFFFF\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png\u00bb title_text=\u00bbwortbildmarke-goeg-RGB\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/\u00bb _builder_version=\u00bb4.25.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00bb200px\u00bb custom_margin=\u00bb5px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Gesundheit \u00d6sterreich GmbH (GOEG)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

The Austrian National Public Health Institute (Gesundheit \u00d6sterreich GmbH) es la instituci\u00f3n responsable de la investigaci\u00f3n y planificaci\u00f3n de la sanidad p\u00fablica en Austria. Tambi\u00e9n act\u00faa como centro nacional de competencia y financiaci\u00f3n para la promoci\u00f3n y prevenci\u00f3n de la salud y facilita la investigaci\u00f3n relacionada con la asistencia sanitaria. El GOEG es una sociedad an\u00f3nima p\u00fablica sin \u00e1nimo de lucro, propiedad al 100% de la Rep\u00fablica de Austria, representada por el Ministerio Federal de Asuntos Sociales, Sanidad, Asistencia y Protecci\u00f3n del Consumidor. <\/p>\n

Funci\u00f3n en el proyecto:<\/strong> El GOEG aporta su experiencia en fijaci\u00f3n de precios de medicamentos, pol\u00edticas de fijaci\u00f3n de precios y reembolso de productos farmac\u00e9uticos y dispositivos m\u00e9dicos, y en investigaci\u00f3n comparativa de sistemas farmac\u00e9uticos. Gracias a su colaboraci\u00f3n con los responsables pol\u00edticos, el GOEG tambi\u00e9n contribuye al intercambio de informaci\u00f3n y a la colaboraci\u00f3n entre pa\u00edses en el proyecto. <\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bbrgba(57,60,132,0.15)\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/university-of-oslo.png\u00bb title_text=\u00bbuniversidad de oslo\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=\u00bb5px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Universitetet i Oslo <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Universitetet i Oslo (UiO) es la universidad m\u00e1s grande y antigua de Noruega. Tiene 27.700 alumnos y 6.000 empleados. La universidad consta de cinco facultades que investigan e imparten ense\u00f1anza en teolog\u00eda, derecho, medicina, humanidades, matem\u00e1ticas y ciencias naturales, odontolog\u00eda y ciencias sociales. Las actividades fundamentales de la Facultad de Medicina son la investigaci\u00f3n, la educaci\u00f3n, la divulgaci\u00f3n y la innovaci\u00f3n en beneficio de los pacientes y la sociedad. <\/p>\n

Funci\u00f3n en el proyecto: <\/strong>La UiO contribuye en las aplicaciones reales de medicamentos de precisi\u00f3n contra el c\u00e1ncer y productos sanitarios, y con su experiencia en ETS, modelizaci\u00f3n de simulaci\u00f3n matem\u00e1tica, establecimiento de prioridades y an\u00e1lisis de datos de registro.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#FFFFFF\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24.png\u00bb title_text=\u00bbAIM-LOGO_png24″ url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00bb150px\u00bb custom_margin=\u00bb5px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Asociaci\u00f3n Internacional de Mutualidades (AIM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

La AIM es una organizaci\u00f3n internacional que agrupa a las federaciones de mutuas sanitarias y organismos estatutarios y complementarios de seguros por enfermedad.
El trabajo de sus miembros se basa en la solidaridad, el trabajo sin \u00e1nimo de lucro y la democracia en toda Europa, Am\u00e9rica Latina, \u00c1frica y Oriente Medio.
La AIM aboga por la igualdad de acceso a la salud y la asistencia, el precio justo de los medicamentos, una digitalizaci\u00f3n al servicio de los asegurados, la integraci\u00f3n de la salud en todas las pol\u00edticas y una mayor atenci\u00f3n a la prevenci\u00f3n.<\/p>\n

Funci\u00f3n en el proyecto:<\/strong> El algoritmo innovador que combina asequibilidad y apoyo a la innovaci\u00f3n valiosa ser\u00e1 la base del modelo de precios innovador en ASCERTAIN.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb background_color=\u00bbrgba(133,184,189,0.3)\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png\u00bb title_text=\u00bbLogotipo EHA – Negro\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/\u00bb _builder_version=\u00bb4.27.0″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00bb150px\u00bb custom_margin=\u00bb||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

European Hematology Association <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

European Hematology Association (EHA) – La EHA es una organizaci\u00f3n no gubernamental y sin \u00e1nimo de lucro guiada por su misi\u00f3n de promover la excelencia en la atenci\u00f3n al paciente, la investigaci\u00f3n y la educaci\u00f3n en hematolog\u00eda. La EHA es la mayor organizaci\u00f3n con sede en Europa que re\u00fane a profesionales m\u00e9dicos, investigadores y cient\u00edficos interesados en hematolog\u00eda. La EHA representa a la hematolog\u00eda y a los hemat\u00f3logos en el \u00e1mbito pol\u00edtico y normativo europeo para mejorar la regulaci\u00f3n, aumentar la disponibilidad y asequibilidad de los medicamentos y armonizar la educaci\u00f3n y formaci\u00f3n de los hemat\u00f3logos. <\/p>\n

Funci\u00f3n en el proyecto: <\/strong>aporta su experiencia en fijaci\u00f3n de precios y rentabilidad.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#FFFFFF\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo.png\u00bb title_text=\u00bbChino.io – logotipo\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=\u00bb||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Chino.io (CHINO)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Chino SRL es una empresa italiana de ciberseguridad y tecnolog\u00eda en la nube fundada en 2014 con la misi\u00f3n de ayudar a los desarrolladores de aplicaciones sanitarias a resolver los problemas de seguridad y de cumplimiento de la ley de privacidad cuando tratan con datos sanitarios sensibles en la nube. Chino SRL ha creado una plataforma de desarrollo de software llamada Chino.io. La plataforma ofrece a los desarrolladores un conjunto de API para almacenar, compartir y gestionar datos sanitarios sensibles de forma segura y cumplir plenamente todas las leyes de protecci\u00f3n de datos, incluidas GDPR, e-Privacy e HIPAA. <\/p>\n

Funci\u00f3n en el proyecto:<\/strong> <\/span><\/strong>Gesti\u00f3n de datos y \u00e9tica en el WP2.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#fbedec\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo.png\u00bb title_text=\u00bbLogotipo MPE\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00bb100px\u00bb custom_margin=\u00bb||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Myeloma Patients Europe (MPE)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Myeloma Patients Europe (MPE) es una organizaci\u00f3n paraguas de grupos de pacientes de mieloma y amiloidosis de cadenas ligeras de inmunoglobulina de toda Europa y cuenta actualmente con 53 miembros en 33 pa\u00edses. La misi\u00f3n de la organizaci\u00f3n es proporcionar educaci\u00f3n, informaci\u00f3n y apoyo a los grupos miembros y defender a nivel europeo, nacional y local la mejor investigaci\u00f3n posible y la igualdad de acceso a tratamiento y cuidados. Para lograr sus objetivos, la MPE trabaja directamente con los miembros, profesionales sanitarios, autoridades de reembolso, reguladores, pol\u00edticos, empresas farmac\u00e9uticas y medios de comunicaci\u00f3n, a fin de garantizar que todas las partes interesadas colaboren para mejorar los resultados de los pacientes y reducir las desigualdades en toda Europa. <\/p>\n

Funci\u00f3n en el proyecto:<\/strong> participaci\u00f3n de los pacientes, identificaci\u00f3n de sus necesidades y preferencias para el desarrollo de modelos.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb background_color=\u00bbRGBA(255,255,255,0)\u00bb custom_padding=\u00bb45px||45px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4″ use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00bb|25px|||false|false\u00bb custom_css_main_element=\u00bbwidth:20.65% !important;\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg\u00bb title_text=\u00bbOptiMedis_RGB\u00bb url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00bb130px\u00bb custom_margin=\u00bb||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#393C84″ header_2_font=\u00bbPoppins semibold|||on|||||\u00bb header_2_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||22px||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

OptiMedis AG (OM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

OptiMedis es una empresa de gesti\u00f3n y an\u00e1lisis de datos sanitarios registrada en Alemania. Su actividad principal es desarrollar y gestionar sistemas regionales de prestaci\u00f3n de asistencia integrada con redes de m\u00e9dicos y otros proveedores. El enfoque de OptiMedis para transformar los sistemas de asistencia sanitaria ha sido reconocido con frecuencia por la UE, m\u00faltiples proyectos de investigaci\u00f3n de la UE, el Fondo de la Commonwealth, el Centro Duke Margolis de Pol\u00edtica Sanitaria, la OMS, el Banco Mundial y otros. OptiMedis gestiona tres Sistemas Integrados de Prestaci\u00f3n de Asistencia en Alemania, con una poblaci\u00f3n de m\u00e1s de 120.000 personas y en los que participan m\u00e1s de 150 proveedores de asistencia sanitaria. OptiMedis participa actualmente en proyectos competitivos de investigaci\u00f3n e implantaci\u00f3n con un volumen de m\u00e1s de 10 millones de euros. <\/p>\n

Funci\u00f3n en el proyecto:<\/strong> Actividades de difusi\u00f3n y explotaci\u00f3n del proyecto, fabricaci\u00f3n ecol\u00f3gica de tecnolog\u00eda sanitaria.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/\u00bb button_text=\u00bb\u00a1Ver equipo!\u00bb button_alignment=\u00bbleft\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_bg_color=\u00bbRGBA(255,255,255,0)\u00bb custom_padding_last_edited=\u00bboff|phone\u00bb button_font_last_edited=\u00bboff|desktop\u00bb global_colors_info=\u00bb{}\u00bb button_bg_enable_color__hover=\u00bbon\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ module_id=\u00bbcontacto\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb background_color=\u00bb#86B8BD\u00bb custom_margin=\u00bb||||false|false\u00bb custom_padding=\u00bb16px||75px||false|false\u00bb box_shadow_style=\u00bbpreset7″ box_shadow_horizontal=\u00bb0px\u00bb box_shadow_vertical=\u00bb-274px\u00bb box_shadow_color=\u00bb#FFFFFF\u00bb global_module=\u00bb910″ saved_tabs=\u00bball\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins semibold|||on|||||\u00bb header_font_size=\u00bb36px\u00bb custom_margin=\u00bb14px||23px||false|false\u00bb custom_margin_tablet=\u00bb\u00bb custom_margin_phone=\u00bb||30px||false|false\u00bb custom_margin_last_edited=\u00bbon|phone\u00bb header_font_size_phone=\u00bb24px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Contacto<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins regular||||||||\u00bb text_text_color=\u00bb#393C84″ text_font_size=\u00bb24px\u00bb text_line_height=\u00bb1.33em\u00bb module_alignment=\u00bbright\u00bb custom_margin=\u00bb||0px||false|false\u00bb text_font_size_tablet=\u00bb\u00bb text_font_size_phone=\u00bb18px\u00bb text_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Ponte en contacto con nosotros si tienes alguna pregunta o comentario. Nos pondremos en contacto contigo lo antes posible. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_3,1_3,1_3″ use_custom_gutter=\u00bbon\u00bb module_class=\u00bbtablet-three-cols\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb max_width_tablet=\u00bb980px\u00bb max_width_phone=\u00bb500px\u00bb max_width_last_edited=\u00bbon|phone\u00bb custom_padding=\u00bb0px|30px|0px|30px|false|true\u00bb global_colors_info=\u00bb{}\u00bb custom_css_main_element_last_edited=\u00bbon|phone\u00bb custom_css_main_element_tablet=\u00bbdisplay:flex;\u00bb custom_css_main_element_phone=\u00bbdisplay:flex; flex-direction:column;\u00bb][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00bb global_colors_info=\u00bb{}\u00bb custom_css_main_element_last_edited=\u00bbon|tablet\u00bb custom_css_main_element_tablet=\u00bbmargin-bottom:0;\u00bb custom_css_main_element_phone=\u00bbmargin-bottom:20px;\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png\u00bb title_text=\u00bbCarin_Uyl-de-Groot\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb link_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Para preguntas relacionadas con la investigaci\u00f3n:<\/p>\n

Carin Uyl-de Groot<\/strong>
Coordinadora del proyecto<\/p>\n

Universidad Erasmus de Rotterdam
uyl@eshpm.eur.nl<\/a>
Tel\u00e9fono: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00bb background_color=\u00bb#393C84″ global_colors_info=\u00bb{}\u00bb custom_css_main_element_last_edited=\u00bbon|phone\u00bb custom_css_main_element_tablet=\u00bbmargin-bottom:0;\u00bb custom_css_main_element_phone=\u00bbmargin-bottom:20px;\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png\u00bb title_text=\u00bbMarcel-Langone\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.20.2″ _module_preset=\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb link_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Para preguntas generales sobre el proyecto:<\/p>\n

Marcel Langone Marques<\/strong>
Director del proyecto<\/p>\n

Universidad Erasmus de Rotterdam
marcel.langonemarques@eur.nl<\/a>
Tel\u00e9fono: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.20.2″ _module_preset=\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00bb background_color=\u00bb#048EA3″ global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png\u00bb title_text=\u00bbMi proyecto-1 (7)\u00bb _builder_version=\u00bb4.21.0″ _module_preset=\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.20.2″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb link_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

Para comunicaciones:<\/p>\n

Lena Jessen<\/strong>
Gestora del proyecto<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
Tel\u00e9fono: +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ConsorcioEsta secci\u00f3n ofrece una visi\u00f3n general del consorcio del proyecto ASCERTAIN, incluyendo informaci\u00f3n sobre los socios del proyecto y sus respectivas funciones y responsabilidades. Somos un consorcio de socios de siete pa\u00edses (Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia) que colaboramos juntos.Erasmus Universiteit RotterdamErasmus Universiteit Rotterdam (EUR) se encuentra en R\u00f3terdam (Pa\u00edses Bajos), y cuenta con 3.700 miembros de personal acad\u00e9mico y 23.867 estudiantes. Erasmus School of Health Policy & Management (ESHPM) es una escuela multidisciplinar de investigaci\u00f3n y ense\u00f1anza de la universidad. Uno de sus departamentos, Institute for Medical Technology Assessment (iMTA), ha desempe\u00f1ado un papel clave en la investigaci\u00f3n sobre ETS en Pa\u00edses Bajos, Europa y el resto del mundo. El instituto ha llevado a cabo m\u00e1s de 600 proyectos de investigaci\u00f3n sanitaria patrocinados por importantes organismos de financiaci\u00f3n, como gobiernos o instituciones relacionadas con el gobierno, la Comisi\u00f3n Europea, la OMS, organizaciones sanitarias, fundaciones ben\u00e9ficas y la industria farmac\u00e9utica. Funci\u00f3n en el proyecto: EUR es el coordinador de este proyecto y aporta su experiencia en fijaci\u00f3n de precios, terapia g\u00e9nica y celular y reembolso.Comenius University in Bratislava (UNIBA)Comenius University in Bratislava es una instituci\u00f3n de investigaci\u00f3n que dirige cientos de proyectos nacionales e internacionales. Un […]<\/p>\n","protected":false},"author":1,"featured_media":3967,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3966","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nConsorcio - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/es\/consorcio\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consorcio\" \/>\n<meta property=\"og:description\" content=\"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/es\/consorcio\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T08:12:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"22 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/\",\"name\":\"Consorcio - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"datePublished\":\"2023-03-03T16:32:28+00:00\",\"dateModified\":\"2025-06-24T08:12:35+00:00\",\"description\":\"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"width\":1254,\"height\":836,\"caption\":\"10 partners from 7 different countries work together on ASCERTAIN\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/consorcio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/es\\\/pagina-de-inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consorcio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Consorcio - ASCERTAIN","description":"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/es\/consorcio\/","og_locale":"es_ES","og_type":"article","og_title":"Consorcio","og_description":"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.","og_url":"https:\/\/www.access2meds.eu\/es\/consorcio\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T08:12:35+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Tiempo de lectura":"22 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/","url":"https:\/\/www.access2meds.eu\/es\/consorcio\/","name":"Consorcio - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","datePublished":"2023-03-03T16:32:28+00:00","dateModified":"2025-06-24T08:12:35+00:00","description":"El proyecto ASCERTAIN re\u00fane a diez socios de siete pa\u00edses: Austria, B\u00e9lgica, Pa\u00edses Bajos, Eslovaquia, Noruega, Alemania e Italia.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/es\/consorcio\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","width":1254,"height":836,"caption":"10 partners from 7 different countries work together on ASCERTAIN"},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/es\/consorcio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/es\/pagina-de-inicio\/"},{"@type":"ListItem","position":2,"name":"Consorcio"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/pages\/3966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/comments?post=3966"}],"version-history":[{"count":19,"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/pages\/3966\/revisions"}],"predecessor-version":[{"id":4521,"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/pages\/3966\/revisions\/4521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/media\/3967"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/es\/wp-json\/wp\/v2\/media?parent=3966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}